Predictive performance of ten equations for estimating creatinine clearance in cardiac patients. Iohexol Cooperative Study Group

OBJECTIVE: The predictive performance of 10 equations used to estimate creatinine clearance (Clcr) was assessed retrospectively from data collected on 420 patients. DESIGN: This study is a retrospective data analysis of information collected on hemodynamically stable patients awaiting coronary angiography during the Iohexol Cooperative Study. SETTING: The Iohexol Cooperative Study was a multicenter study that compared nephrotoxicity of high- and low-osmolar contrast media in patients undergoing coronary angiography. Data used for this analysis were preangiography 24-hour urine collections that were primarily collected in hospitalized patients. PATIENTS: Patients selected from the Iohexol Cooperative Study database for analysis were participants categorized into one or more of six subgroups: elderly (n = 222), hypoalbuminemic (n = 25), chronic renal insufficiency (n = 128), low serum creatinine (n = 115), obese (n = 208), and diabetic (n = 191) who had baseline urine collections of at least 24 hours. OUTCOME MEASURES: Predictive performance was assessed using bias, precision, slopes, and y-intercepts. RESULTS: The Salazar-Corcoran equation was unbiased in the entire group as well as in five of the subgroups. The Cockcroft-Gault equation was unbiased in three of the subgroups. All other equations were biased in predicting Clcr in the entire group as well as in at least four of the subgroups. Precision was generally poor. All slopes were significantly different than one and all y-intercepts were significantly different than zero (p < 0.01). Correlation coefficients were between 0.63 and 0.79 with the exceptions of the low serum creatinine subgroup (r values 0.35-0.64) and the Davis-Chandler equation (r values 0.35-0.71 across groups). CONCLUSIONS: Of the equations studied, Salazar-Corcoran and Cockcroft-Gault appear to be the best for predicting Clcr.

This article has been cited by other articles:

				E. Raichlin, A. Prasad, V. Mathew, B. Kent, D. R. Holmes Jr, G. M. Pumper, R. E. Nelson, L. O. Lerman, and A. Lerman Efficacy and Safety of Atrasentan in Patients With Cardiovascular Risk and Early Atherosclerosis Hypertension, September 1, 2008; 52(3): 522 - 528. [Abstract] [Full Text] [PDF]

				P. Lim, J.-P. Collet, S. Moutereau, N. Guigui, L. Mitchell-Heggs, S. Loric, M. Bernard, S. Benhamed, G. Montalescot, J.-L. D. Rande, et al. Fetuin-A Is an Independent Predictor of Death after ST-Elevation Myocardial Infarction Clin. Chem., October 1, 2007; 53(10): 1835 - 1840. [Abstract] [Full Text] [PDF]

				M. P. Pai, J. P. Norenberg, T. Anderson, D. W. Goade, K. A. Rodvold, R. A. Telepak, and R.-C. Mercier Influence of Morbid Obesity on the Single-Dose Pharmacokinetics of Daptomycin Antimicrob. Agents Chemother., August 1, 2007; 51(8): 2741 - 2747. [Abstract] [Full Text] [PDF]

				K. Lietz, J. W. Long, A. G. Kfoury, M. S. Slaughter, M. A. Silver, C. A. Milano, J. G. Rogers, Y. Naka, D. Mancini, and L. W. Miller Outcomes of Left Ventricular Assist Device Implantation as Destination Therapy in the Post-REMATCH Era: Implications for Patient Selection Circulation, July 31, 2007; 116(5): 497 - 505. [Abstract] [Full Text] [PDF]

				G. V. Raj, A. Iasonos, H. Herr, and S. M. Donat Formulas Calculating Creatinine Clearance Are Inadequate for Determining Eligibility for Cisplatin-Based Chemotherapy in Bladder Cancer J. Clin. Oncol., July 1, 2006; 24(19): 3095 - 3100. [Abstract] [Full Text] [PDF]

				A. C. Mita, C. J. Sweeney, S. D. Baker, A. Goetz, L. A. Hammond, A. Patnaik, A. W. Tolcher, M. Villalona-Calero, A. Sandler, T. Chaudhuri, et al. Phase I and Pharmacokinetic Study of Pemetrexed Administered Every 3 Weeks to Advanced Cancer Patients With Normal and Impaired Renal Function J. Clin. Oncol., February 1, 2006; 24(4): 552 - 562. [Abstract] [Full Text] [PDF]

				P. Delanaye, R. P. Radermecker, M. Rorive, G. Depas, and J. M. Krzesinski Indexing glomerular filtration rate for body surface area in obese patients is misleading: concept and example Nephrol. Dial. Transplant., October 1, 2005; 20(10): 2024 - 2028. [Full Text] [PDF]

				B. A. Perkins, R. G. Nelson, B. E.P. Ostrander, K. L. Blouch, A. S. Krolewski, B. D. Myers, and J. H. Warram Detection of Renal Function Decline in Patients with Diabetes and Normal or Elevated GFR by Serial Measurements of Serum Cystatin C Concentration: Results of a 4-Year Follow-Up Study J. Am. Soc. Nephrol., May 1, 2005; 16(5): 1404 - 1412. [Abstract] [Full Text] [PDF]

				D. N. Wijeysundera, V. Rao, W. S. Beattie, J. Ivanov, and K. Karkouti Evaluating Surrogate Measures of Renal Dysfunction After Cardiac Surgery Anesth. Analg., May 1, 2003; 96(5): 1265 - 1273. [Abstract] [Full Text] [PDF]

				D. Abramov, M. Tamariz, S. Fremes, S. Tobe, G. Christakis, V. Guru, and B. Goldman Impact of Preoperative Renal Dysfunction on Cardiac Surgery Results Asian Cardiovasc Thorac Ann, March 1, 2003; 11(1): 42 - 47. [Abstract] [Full Text] [PDF]

				A. G. Bostom, F. Kronenberg, and E. Ritz Predictive Performance of Renal Function Equations for Patients with Chronic Kidney Disease and Normal Serum Creatinine Levels J. Am. Soc. Nephrol., August 1, 2002; 13(8): 2140 - 2144. [Abstract] [Full Text] [PDF]

				M. G. Gamoso, B. Phillips-Bute, K. P. Landolfo, M. F. Newman, and M. Stafford-Smith Off-Pump Versus On-Pump Coronary Artery Bypass Surgery and Postoperative Renal Dysfunction Anesth. Analg., November 1, 2000; 91(5): 1080 - 1084. [Abstract] [Full Text] [PDF]

				M. Stafford-Smith, B. Phillips-Bute, D. N. Reddan, J. Black, and M. F. Newman The Association of {epsilon}-Aminocaproic Acid with Postoperative Decrease in Creatinine Clearance in 1502 Coronary Bypass Patients Anesth. Analg., October 1, 2000; 91(5): 1085 - 1090. [Abstract] [Full Text] [PDF]